Shares of Lantheus Holdings cratered 20.5% to $79.49 on September 23, after Curium withdrew and refiled its antitrust paperwork with federal regulators — a move that reopens scrutiny of the $8 billion takeover and signals the deal's path to closing just got harder. The selloff came even as Lantheus announced FDA approval of a new cancer treatment drug on September 22 , a milestone that did nothing to calm investor nerves about whether the biggest radiopharmaceutical merger in history will actually happen.
The Antitrust Clock Resets, and Investors Are Pricing In Risk. On September 17, Curium voluntarily withdrew its pre-merger filing with the FTC, then resubmitted it on September 21, triggering a fresh 30-day review period expiring October 21, 2026.
That window could be extended further if the FTC requests additional documents. While Lantheus called the move "routine," the stock's plunge to $79.49 — a $23 gap below the $102.50 cash offer price — tells a different story. That spread implies the market now sees serious risk this deal could collapse or face forced asset sales.
Antitrust Overlap Is the Real Concern. The FTC review may be the first real barrier because Lantheus's flagship prostate cancer imaging product holds a dominant position in the U.S. market, and regulators may require the divestiture of some assets. Curium is already Lantheus's European distribution partner and is developing a competing cancer therapy still in late-stage trials. Integrating the two companies' R&D, sales, and compliance systems could take at least two years, and the high acquisition debt will pressure future R&D spending.
A New Drug Approval Couldn't Stop the Bleeding. On September 22, Lantheus won FDA approval for its cancer treatment Bravnetsa through a faster regulatory pathway — the first radioligand therapy ever cleared this way — making it the only drug the FDA considers equivalent to Novartis's established product Lutathera. Under normal circumstances, that would be a major catalyst. But with $388.2 million in quarterly revenue already on the books and the company having reached roughly 7 million patients in 2025 , the market's attention is squarely on whether the deal closes — not the pipeline.
What Happens Next Determines Everything. Both companies say they still expect to close in the first half of 2027. But if the FTC issues a so-called "second request" — essentially a deeper investigation — the timeline could stretch well beyond that. At $79.49, the stock prices in roughly a one-in-four chance the deal falls apart entirely. Shareholders stand to receive up to an additional $12 per share through performance-based payments tied to product sales through 2030 — but only if the merger survives October's regulatory gauntlet.